tiprankstipranks
Insmed completes enrollment in Phase 3 ASPEN study of brensocatib
The Fly

Insmed completes enrollment in Phase 3 ASPEN study of brensocatib

Insmed announced that adult patient enrollment is complete as of today in its pivotal ASPEN study of brensocatib. Insmed anticipates reporting topline data from adults in the ASPEN trial in the second quarter of 2024.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on INSM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles